



General Meeting

ASX:RCE | FSE:R9Q

September 2026

Disclaimer

DISCLAIMER

This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any

potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

FUTURE MATTERS

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US DISCLOSURE

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1933 (“Securities Act”). The Company's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

Recce Pharmaceuticals – Company Overview

Recce Pharmaceuticals is a leading, Australian anti-infective company approaching near term commercialisation milestones



Products address the global healthcare crisis of antibiotic resistance: working faster than traditional antibiotics and against multidrug resistant bacteria



Patient dosing has commenced for Phase 3 clinical trials in Australia and Indonesia of lead asset RECCE® 327 Gel for the treatment of Diabetic Foot Infections – interim data readout expected Q3 CY2026 and **commercialisation in 2027**



Recce has signed a non-binding **term sheet with a leading Middle Eastern pharmaceutical company** for a 10-Year exclusive multi-country licensing agreement



Multiple clinical indications and formulations **addressing unmet medical needs**



Agreements with **US Defense Burn Research Program** and **US Army Medical Research Institute** of Infectious Diseases further support Recce's product potential

RECCE® 327 granted Qualified Infectious Disease Product (QIDP)
Designation by **U.S. Food and Drug Administration** giving **5 years market exclusivity** plus fast-track approval.

RECCE® 327 added to World Health Organization's List of Antibacterial Products in Clinical Development.



Board and Management Structure

Dr John Prendergast – Chairman

BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU)



US-based, current Chairman and Co-founder of Palatin Technologies, Inc. (NYSE: PTN) and Lead Director of Nighthawk Biosciences (NYSE: HHWK). With extensive experience in the international commercialisation of pharmaceutical technologies, **Dr Prendergast has been responsible for the approval of three new drug applications** and played a pivotal role in the successful sale of Vylessi® to Cosette Pharmaceuticals



James Graham – Managing Director & Chief Executive Officer

BCom (Entrepreneurship), GAICD



Mr Graham is the Chief Executive Officer of Recce Pharmaceuticals. He brings extensive experience in marketing, business development, and the commercialisation of early-stage technologies with global potential. With a proven track record of growing globally focused companies, Mr Graham has applied his expertise to Recce, including serving on its Board of Directors. He has participated in nearly every capital raise to date, demonstrating a strong commitment to expanding Recce's commercial opportunities and clinical programs.

Dr Alan Dunton – Chief Medical Advisor & Non-Executive Director

BSc (BioChem) Hons, M.D. (NYU)



US based, Director of Palatin Technologies. Over three decades of senior pharmaceutical experience incl. President and MD of Janssen Research Foundation (Johnson & Johnson). **Dr Dunton has advanced a number of blockbuster antibiotics** through regulatory review and commercialisation at Fortune 500 companies including Roche. **Dr Dunton has been responsible for the approval of approximately 20 New Drug Applications.** Dr. Dunton played a key role in the sale of Vylessi® to Cosette Pharmaceuticals for USD \$159 million in contingent, sales-based milestones, continuing his track record of fostering advancements in drug development and successful commercialisation efforts.



Michele Dilizia – Executive Director & Chief Scientific Officer

BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM



Co-inventor and qualified medical scientist with a specialisation in medical microbiology and regulatory affairs. **Ms Dilizia successfully co-led the research and development of Recce's suite of anti-infective compounds**, resulting in a portfolio of granted patents across the globe, including a Qualified Infectious Disease Product designation with the U.S. FDA.

Dr Justin Ward – Executive Director & Principal Quality Chemist

BSc (Chem), PhD (Chem), M Pharm, MRACI, CChem



A quality control expert who has worked with leading pharmaceutical companies. He previously held a technical role with Pfizer, involving providing data for the regulatory submissions to the FDA and TGA. Dr Ward is bringing Recce's research and development and manufacturing up to US FDA requirements.



Alistair McKeough – Non-Executive Director



Mr McKeough is an experienced executive and solicitor. Before being appointed as a non-executive director in 2022, Alistair served as Recce's company secretary and he has been involved with the company since 2017. Alistair has extensive experience in a variety of private and listed corporations across many sectors, including professional services, technology, financial services, charities, health, biotech, childcare and education. Recent roles include Managing Director of a legal practice specialising in equity capital markets and advice to listed companies and as part of the senior leadership team at share registry, Automic Group.

Registrational Phase 3 Clinical Trial - Indonesia

Study Title: Phase 3, Double-blind, Placebo-Controlled Study of R327 Topical Gel for the Treatment of Diabetic Foot Ulcer Infections

For personal use only

Population



Up to **310 participants** will be enrolled who present with a mild diabetic foot infection.

Interim data analysis to be conducted after **155 participants**.

Locations



Multi-centre, **5 activated sites** across Indonesia.

Over 20.9 million adults in Indonesia are living with diabetes – more than 1 in every 10 adults.

Intervention



Participants to receive either **R327 topical gel** or **placebo topical gel**.

Endpoints



Primary Endpoint: Assess the **clinical response** of the DFI according to the Lipsky Scale.

Secondary Endpoints: DFI total wound score and **safety** of R327G.



Phase 3 DFI Clinical Trial Expands in Australia

HREC approves protocol amendment adding randomised, active-controlled, non-inferiority + superiority component

For personal use only



Study Design

Randomised, active-controlled, non-inferiority design and includes a superiority analysis

Randomised between R327G and one of four physician-selected comparator antibiotics



Strategic Significance

- Phase 3 global regulatory strategy targeting approvals across **Australia (TGA), the US (FDA), MENA and ASEAN**
- **R327G to be positioned as first standard of care treatment for DFIs** - no specific standard of care exists for DFI



Participants


- **208 patients total** with interim analysis to be conducted after 104 participants
- Patient dosing continues under existing protocol
- **Wound imaging added**, calibrated digital photography for standardised, objective assessment



Phase 3 DFI Clinical Trial Expands in Australia & Indonesia

HREC approves protocol amendment adding randomised, active-controlled, non-inferiority component

For personal use only



HREC approval significantly expands DFI patient pool from Mild to Mild + Moderate

	Was	Now
Ulcer	Below ankle	Below knee
Severy	Mild only	Mild to moderate
Criteria	Single ulcer	Per ulcer basis



Large Addressable Market

The global diabetic foot infection (DFI) market represents a substantial burden on global healthcare systems



US\$5.8B

Est. global DFI treatment market¹



US\$135.4B

Est. global market opportunities in the anti-infectives market²

INDONESIA

>20 million

adults in Indonesia with diabetes³

MENA

>84 million

adults in MENA region with diabetes⁴

GLOBAL

>589 million


adults globally with diabetes⁵

- For adults with diabetes, **approximately one in three adults will develop a diabetic foot ulcer** in their lifetime⁶
- In Indonesia, DFIs are severe in **67.1% of hospitalised cases** and **result in amputation in 46.9% of patients**⁷
- **Diabetes is responsible for 60% of all amputations in Australia**, and it has one of the worst diabetes-related lower limb amputation rates in the developed world, with nearly 20 per 100,000 people with diabetes losing a limb compared to an average of 12 per 100,000 elsewhere.⁸

Source: (1) Grand View Research; Diabetic Foot Ulcer Treatment Market Size, 2025 (2) Grand View Research, Anti-Infective Agents Market Size, 2023 (3) Diabetes Atlas, International Diabetes Federation (IDF) and Prof EM Yunir, Faculty of Medicines, University of Indonesia. (4) <https://diabetesatlas.org/data-by-location/region/middle-east-and-north-africa/> (5) <https://idf.org/about-diabetes/diabetes-facts-figures/> (6) The current burden of diabetic foot disease – PMC (7) <https://doi.org/10.1016/j.heliyon.2024.e41263> (8) <https://westernsydneydiabetes.com.au/framework-for-change/enhanced-management/save-a-leg/>

Program Pipeline* driven by 1st approval in Diabetic Foot Infections

For personal use only



recce.com.au

*The information and forecasts presented reflect management's current expectations as at the date of this presentation. These statements involve assumptions, including the availability of appropriate funding, and are subject to known and unknown risks and uncertainties. Actual outcomes may differ from those expressed or implied and the Company reserves the right to revise its plans, projections, and strategic priorities as circumstances change.

For personal use only

Thank you